+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Anti-Parkinson Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030

  • ID: 5345449
  • Report
  • June 2021
  • Region: Global
  • The Business Research Company

FEATURED COMPANIES

  • 1 A Pharma
  • Dr. Reddy’s
  • Merck
  • Pfizer
  • Teva Pharmaceuticals
  • Wockhardt
Anti-Parkinson Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030 provides the strategists, marketers and senior management with the critical information they need to assess the global anti-parkinson drugs as it emerges from the COVID 19 shut down.







Reasons to Purchase
  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis

Description:

Where is the largest and fastest growing market for the anti-parkinson drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Anti-Parkinson Drugs market global report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider anti-parkinson drugs market, and compares it with other markets.
  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, the impact of the COVID 19 virus and forecasting its recovery.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the impact and recovery trajectory of COVID 19 for all regions, key developed countries and major emerging markets.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
  • The anti-parkinson drugs market section of the report gives context. It compares the anti-parkinson drugs market with other segments of the anti-parkinson drugs market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, anti-parkinson drugs indicators comparison.

Scope

Markets Covered:

1) By Drugs Class: Levodopa/Carbidopa; Dopamine Receptor Agonists; Monoamine Oxidase Type B (MAO-B) Inhibitors; Catechol-O-Methyltransferase (COMT)-inhibitors; Anticholinergics; Other Drugs
2) By Route of Administration: Oral; Injection; Transdermal
3) By Distribution Channel: Hospital Pharmacies; Retailer Pharmacies; Online Pharmacies

Companies Mentioned: GlaxoSmithKline plc; Pfizer; UCB; Novartis; Roche

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

Data segmentations: Country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Frequently Asked Questions about the Global Anti-Parkinson Drugs Market

What is the estimated value of the Global Anti-Parkinson Drugs Market?

The Global Anti-Parkinson Drugs Market was estimated to be valued at $5.6 billion in 2021.

What is the growth rate of the Global Anti-Parkinson Drugs Market?

The growth rate of the Global Anti-Parkinson Drugs Market is 8.8%, with an estimated value of $7.8 billion by 2025.

What is the forecasted size of the Global Anti-Parkinson Drugs Market?

The Global Anti-Parkinson Drugs Market is estimated to be worth $7.8 billion by 2025.

Who are the key companies in the Global Anti-Parkinson Drugs Market?

Key companies in the Global Anti-Parkinson Drugs Market include GlaxoSmithKline plc, Pfizer, Merck, Novartis, Roche, UCB S.A, Teva Pharmaceuticals, AbbVie Inc. and Boehringer Ingelheim.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • 1 A Pharma
  • Dr. Reddy’s
  • Merck
  • Pfizer
  • Teva Pharmaceuticals
  • Wockhardt

1. Executive Summary2. Anti-Parkinson Drugs Market Characteristics3. Anti-Parkinson Drugs Market Trends And Strategies4. Impact Of COVID-19 On Anti-Parkinson Drugs
5. Anti-Parkinson Drugs Market Size And Growth
5.1. Global Anti-Parkinson Drugs Historic Market, 2015-2020, $ Billion
5.1.1. Drivers Of The Market
5.1.2. Restraints On The Market
5.2. Global Anti-Parkinson Drugs Forecast Market, 2020-2025F, 2030F, $ Billion
5.2.1. Drivers Of The Market
5.2.2. Restraints On the Market
6. Anti-Parkinson Drugs Market Segmentation
6.1. Global Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Levodopa/Carbidopa
  • Dopamine Receptor Agonists
  • Monoamine Oxidase Type B (MAO-B) Inhibitors
  • Catechol-O-Methyltransferase (COMT)-inhibitors
  • Anticholinergics
  • Other Drugs
6.2. Global Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Oral
  • Injection
  • Transdermal
6.3. Global Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Hospital Pharmacies
  • Retailer Pharmacies
  • Online Pharmacies

7. Anti-Parkinson Drugs Market Regional And Country Analysis
7.1. Global Anti-Parkinson Drugs Market, Split By Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
7.2. Global Anti-Parkinson Drugs Market, Split By Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
8. Asia-Pacific Anti-Parkinson Drugs Market
8.1. Asia-Pacific Anti-Parkinson Drugs Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
8.3. Asia-Pacific Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
9. China Anti-Parkinson Drugs Market
9.1. China Anti-Parkinson Drugs Market Overview
9.2. China Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F,$ Billion
9.3. China Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2020, 2020-2025F, 2030F,$ Billion
10. India Anti-Parkinson Drugs Market
10.1. India Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
10.2. India Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
11. Japan Anti-Parkinson Drugs Market
11.1. Japan Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
11.2. Japan Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
12. Australia Anti-Parkinson Drugs Market
12.1. Australia Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
12.2. Australia Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
13. Indonesia Anti-Parkinson Drugs Market
13.1. Indonesia Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
13.2. Indonesia Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
14. South Korea Anti-Parkinson Drugs Market
14.1. South Korea Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
14.2. South Korea Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
15. Western Europe Anti-Parkinson Drugs Market
15.1. Western Europe Anti-Parkinson Drugs Market Overview
15.2. Western Europe Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
15.3. Western Europe Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
16. UK Anti-Parkinson Drugs Market
16.1. UK Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
16.2. UK Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
17. Germany Anti-Parkinson Drugs Market
17.1. Germany Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
17.2. Germany Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
18. France Anti-Parkinson Drugs Market
18.4. France Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
18.5. France Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
19. Eastern Europe Anti-Parkinson Drugs Market
19.1. Eastern Europe Anti-Parkinson Drugs Market Overview
19.2. Eastern Europe Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
19.3. Eastern Europe Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
20. Russia Anti-Parkinson Drugs Market
20.1. Russia Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
20.2. Russia Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
21. North America Anti-Parkinson Drugs Market
21.1. North America Anti-Parkinson Drugs Market Overview
21.2. North America Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
21.3. North America Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
22. USA Anti-Parkinson Drugs Market
22.1. USA Anti-Parkinson Drugs Market Overview
22.2. USA Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
22.3. USA Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
23. South America Anti-Parkinson Drugs Market
23.1. South America Anti-Parkinson Drugs Market Overview
23.2. South America Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
23.3. South America Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
24. Brazil Anti-Parkinson Drugs Market
24.1. Brazil Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
24.2. Brazil Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
25. Middle East Anti-Parkinson Drugs Market
25.1. Middle East Anti-Parkinson Drugs Market Overview
25.2. Middle East Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
25.3. Middle East Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
26. Africa Anti-Parkinson Drugs Market
26.1. Africa Anti-Parkinson Drugs Market Overview
26.2. Africa Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
26.3. Africa Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
27. Anti-Parkinson Drugs Market Competitive Landscape And Company Profiles
27.1. Anti-Parkinson Drugs Market Competitive Landscape
27.2. Anti-Parkinson Drugs Market Company Profiles
27.2.1. GlaxoSmithKline plc
27.2.1.1. Overview
27.2.1.2. Products and Services
27.2.1.3. Strategy
27.2.1.4. Financial Performance
27.2.2. Pfizer
27.2.2.1. Overview
27.2.2.2. Products and Services
27.2.2.3. Strategy
27.2.2.4. Financial Performance
27.2.3. Merck
27.2.3.1. Overview
27.2.3.2. Products and Services
27.2.3.3. Strategy
27.2.3.4. Financial Performance
27.2.4. Novartis
27.2.4.1. Overview
27.2.4.2. Products and Services
27.2.4.3. Strategy
27.2.4.4. Financial Performance
27.2.5. Roche
27.2.5.1. Overview
27.2.5.2. Products and Services
27.2.5.3. Strategy
27.2.5.4. Financial Performance
28. Anti-Parkinson Drugs Pipeline Analysis29. Key Mergers And Acquisitions In The Anti-Parkinson Drugs Market30. Anti-Parkinson Drugs Market Future Outlook and Potential Analysis
31. Appendix
31.1. Abbreviations
31.2. Currencies
31.3. Research Inquiries
31.4. About the Publisher
31.5. Copyright And Disclaimer
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • 1 A Pharma
  • Dr. Reddy’s
  • Merck
  • Pfizer
  • Teva Pharmaceuticals
  • Wockhardt
Major players in the Anti-Parkinson drugs market are GlaxoSmithKline plc, Pfizer, Merck, Novartis, Roche, UCB S.A, Teva Pharmaceuticals, AbbVie Inc. and Mylan.

The global anti-parkinson drugs market is expected to grow from $5.3 billion in 2020 to $5.55 billion in 2021 at a compound annual growth rate (CAGR) of 4.7%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $7.78 billion in 2025 at a CAGR of 9%.

The Anti-Parkinson drugs market consists of sales of drugs used for treating Parkinson's disease (PD), generated by the establishments that manufacture these drugs. Parkinson's disease is a neurodegenerative disorder that affects predominately dopaminergic neurons in a specific area of the brain named substantia nigra and disturbs the movement of the body. People suffering from PD may experience tremor, bradykinesia, limb rigidity, gait, and balance problems.

The anti-Parkinson drugs market covered in this report is segmented by drugs class into levodopa/carbidopa; dopamine receptor agonists; monoamine oxidase type b (MAO-b) inhibitors; catechol-o-methyltransferase (COMT)-inhibitors; anticholinergics; other drugs. It is also segmented by route of administration into oral; injection; transdermal and by distribution channel into hospital pharmacies; retailer pharmacies; online pharmacies.

Increasing investments by governments and companies for Parkinson’s disease drug R&D is a major trend in the anti-Parkinson drugs market. For instance, according to the report published in 2018 by the Parkinson’s Foundation, the foundation awarded $6 million to Parkinson's disease (PD) research. In January 2019, Parkinson’s UK Research and Support charity in the United Kingdom announced a research investment of $1.9 million (£1.5 million) into its drug discovery program to develop novel gene transcription modulators for Parkinson’s disease. Hence, increasing investments in Parkinson’s drug development are expected to drive the anti-Parkinson's drugs market.

In June 2019, AbbVie Inc., a global research-driven biopharmaceutical company, announced the acquisition of Allergan plc, a Dublin-based pharmaceutical company, for an amount of $63 billion. With Allergan’s diversified product portfolio, AbbVie Inc.is expected to strengthen the company’s position in international biopharmaceutical markets. AbbVie Inc. invested in neuroscience, multiple sclerosis, Alzheimer’s disease, and investigating potential disease for Parkinson’s disease. Allergan plc is a pharmaceutical company engaged in developing, manufacturing, and commercializing branded pharmaceutical, biologic, surgical, device, and regenerative medicine products for patients worldwide.

The increasing geriatric population and surging cases of Parkinson's disease (PD) are projected to drive the demand for the anti-Parkinson drugs market. PD commonly occurs in people over the age of 60 years. According to the United Nations Department of Economic and Social Affairs, one in 11 people in the world was over the age of 65 in 2019 and this number is expected to increase to one in six people by the end of 2050. Furthermore, according to the Michael J. Fox Foundation for Parkinson’s Research’s statistics published in June 2019, over 1 million Americans live with PD. Degeneration of neurons in the geriatric population and the surge in cases of Parkinson’s disease is therefore driving the market growth.

The high cost of Parkinson’s disease treatment is anticipated to limit the growth of anti-Parkinson's drugs market over the forecast period. According to the Michael J. Fox Foundation for Parkinson’s Research’s statistics published in June 2019, the economic burden of Parkinson’s disease on patients, families, and the federal governments is increasing. In the United States, the overall cost of Parkinson’s disease to individuals, families, and government is $51.9 billion annually, with $25.4 billion on direct medical costs (including hospitalization and medication). Thus, the high cost of Parkinson's disease treatment is expected to impact the anti-Parkinson drugs market.
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • GlaxoSmithKline plc
  • Pfizer
  • Merck
  • Novartis
  • Roche
  • UCB S.A
  • Teva Pharmaceuticals
  • AbbVie Inc.
  • Mylan
  • Boehringer Ingelheim
  • Orion Pharma
  • ACADIA Pharmaceuticals Inc
  • Sun Pharma
  • Wockhardt
  • Dr. Reddy’s
  • Intas
  • US WorldMeds
  • Zydus Cadila
  • Cipla
  • Strides
  • 1 A Pharma
  • Upsher-Smith
  • Lundbeck
  • Vertical Pharmaceuticals, LLC
  • Zambon Pharmaceuticals
  • M Somerset Pharmaceuticals Inc.
  • Wockhardt
Note: Product cover images may vary from those shown

Loading
LOADING...